Researchers investigated the relationship between eosinophilic esophagitis at the time of diagnosis and disease severity, and the change in disease before and after treatment.
While food allergies may affect response to the medication, environmental allergies do not, the report says.
The monoclonal antibody showed significantly reduced eosinophils in the esophagus and patient-reported symptoms scores
Dupilumab is an interleukin-4 receptor alpha antagonist.
Research presented at ACAAI 2021 assessed associations between IBD, eosinophilic esophagitis, esophageal eosinophilia, and atopic disease in children.
Tezepelumab is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Weekly dupilumab improved disease-specific health-related quality of life and symptom burden in adolescent and adult patients with eosinophilic esophagitis.
Budesonide oral suspension improved histologic, endoscopic, and both histologic and symptomatic outcomes in children with eosinophilic esophagitis compared with placebo.
Researchers evaluated the potential predictive characteristics of eosinophilic esophagitis following IBD diagnosis in children.
Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.
